Welcome!

News Feed Item

National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session

Patient-centered recommendations for people needing additional cholesterol reduction

PHILADELPHIA, PA--(Marketwired - May 19, 2017) - The National Lipid Association (NLA) assembled a panel of experts to update its guidance for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy made in the NLA Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 in 2015.

According to the expert panel, "Recent studies have demonstrated the efficacy of [PCSK9 inhibitors] in reducing LDL cholesterol and non-HDL cholesterol and have confirmed their excellent safety profile."

The expert panel was chaired by Carl Orringer, MD, FNLA, past president of the NLA and associate professor of medicine at the University of Miami School of Medicine, and Terry Jacobson, MD, FNLA, past president of the NLA, professor of medicine, and Director of the Office of Health Promotion and Disease Prevention at Emory University.

The expert panel provided the following recommendations on behalf of the NLA:

                                                                            
----------------------------------------------------------------------------
    2017 Recommendations of the NLA Expert Panel on Treatment with PCSK9    
                                 Inhibitors                                 
----------------------------------------------------------------------------
ASCVD                                                                       
1. PCSK9 inhibitor therapy should be considered for ASCVD risk reduction in 
patients with stable atherosclerotic cardiovascular disease, particularly in
those with additional ASCVD risk factors, on maximally-tolerated statin     
therapy +/- ezetimibe, with on-treatment LDL-C ≥70 mg/dL or non-HDL-C 
≥100 mg/dL. Strength A, Quality: High                                 
----------------------------------------------------------------------------
2. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in     
patients with progressive atherosclerotic cardiovascular disease on         
maximally tolerated-statin therapy +/- ezetimibe, and on-treatment LDL-C    
≥70 mg/dL or non-HDL-C ≥100 mg/dL. Strength B, Quality: Moderate
----------------------------------------------------------------------------
Phenotypic FH/LDL-C ≥ 190 mg/dL                                       
3a. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in    
patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190
mg/dL, no uncontrolled ASCVD risk factors or other key additional high risk 
markers*, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C ≥ 130 
mg/dL on maximal-tolerated statin therapy +/- ezetimibe. Strength B,        
Quality: Moderate                                                           
3b. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in    
patients age 40-79 years with phenotypic FH, pre-treatment LDL-C ≥ 190
mg/dL and the presence of either uncontrolled ASCVD risk factors, key       
additional high risk markers*, or genetic confirmation of familial          
hypercholesterolemia, and on-treatment LDL-C ≥ 70 mg/dL or non-HDL-C  
≥ 100 mg/dL on maximal-tolerated statin +/- ezetimibe. Strength: B,   
Quality: Moderate                                                           
3c. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in    
patients age 18-39 years with phenotypic FH, pre-treatment LDL-C ≥ 190
mg/dL and the presence of either uncontrolled ASCVD risk factors, key       
additional high risk markers*, or genetic confirmation of familial          
hypercholesterolemia, and on-treatment LDL-C ≥ 100 mg/dL or non-HDL-C 
≥ 130 mg/dL on maximal-tolerated statin +/- ezetimibe. Strength: E,   
Quality: Low                                                                
----------------------------------------------------------------------------
3d. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in    
patients with homozygous familial hypercholesterolemia, either of unknown   
genotype, or those known to be LDL receptor defective, on maximal-tolerated 
statin therapy +/- ezetimibe with LDL-C ≥ 70 mg/dL or non-HDL-C       
≥ 100 mg/dL. Strength B, Quality: Moderate                            
----------------------------------------------------------------------------
Very High Risk/Statin Intolerance                                           
4. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in     
selected very high-risk patients who meet the definition of statin          
intolerance (as previously defined by the NLA Statin Expert Panel) and who  
require substantial additional atherogenic cholesterol lowering, despite the
use of other lipid lowering therapies. Strength C, Quality: Low             
----------------------------------------------------------------------------
* Including history of uncontrolled high blood pressure, diabetes, current  
cigarette smoking or family history of premature ASCVD; or additional high  
risk markers (coronary calcium ≥ 300 Agatston units [or ≥ 75th  
percentile for the patient's age, gender and ethnicity]; Lp(a) ≥ 50   
mg/dL using an isoform insensitive assay, hs-CRP ≥ 2 mg/L or CKD      
including albumin/creatinine ratio ≥ 30 mg/g)                         

The other authors on the manuscript are Joseph J. Saseen, PharmD, FNLA, Alan S. Brown, MD, FNLA, Antonio M. Gotto, MD, FNLA, Joyce L. Ross, MSN, CRNP, FNLA, and James A. Underberg, MD, FNLA.

"The National Lipid Association PCSK9 recommendation update provides a comprehensive overview of this class of medication with evidence-based and expert recommendations that allow practitioners to translate the data into high quality patient care," said Orringer, Jacobson and Underberg in a joint statement.

The update is published online in the Journal of Clinical Lipidology.

ABOUT THE NATIONAL LIPID ASSOCIATION
The NLA is a multidisciplinary specialty society focused on prevention of cardiovascular disease and other lipid-related disorders. The NLA's mission is to enhance the practice of lipid management in clinical medicine, and one of its goals is to enhance efforts to reduce death and disability related to disorders of lipid metabolism in patients. Members include physicians (MDs and DOs), as well as clinical team affiliates, from an array of disciplines including PhD researchers, nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians. For more information, visit lipid.org.

Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Underberg,_James-0936c5a09d16b98e8e95eb1f5eb6ffee.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Ross,_Joyce-59cad9e11adf8d3cbc3c28002e93ff55.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Gotto,_Antonio-a5a8676f2c9fbda296080ddf17f4ba67.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Brown,_Alan-cb55ab3150e6b26ca44ae49ecf1adb10.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Saseen_Joe_14_206-c7637a86f6a2bf1ab1e2a3047d30003d.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/jacobson,_Terry-8d80f31b2b339365a179f7e550167b7e.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/Images/Orringer,_Carl-830a5170633eac8eb39aacc0e295326d.jpg

Attachment Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/NLA_PCSK9_2017Rec_Infographic-6eea0ee0aeaab99dabfa055d5aeb266f.pdf
Attachment Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139237/NLA_PCSK9_Update_-_Fact_Sheet-d0b8af5645199474bb93b4440537ba57.pdf

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
While presenting own advanced Robo-Advisory Platform, Michał Różański, Managing Partner at EARP and CEO at Empirica, will illustrate the most important issues of building tailored FinTech software in his session at 20th Cloud Expo. He will share experiences we have gained for over 6 years of developing solutions for financial institutions and FinTech companies, including robo-advisors. We welcome all FinTech innovators interested in how properly implemented technology can move their businesses f...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo Silicon Valley Call for Papers is now open.
As cloud adoption continues to transform business, today's global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
SYS-CON Events announced today that Outscale will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outscale's technology makes an automated and adaptable Cloud available to businesses, supporting them in the most complex IT projects while controlling their operational aspects. You boost your IT infrastructure's reactivity, with request responses that only take a few seconds.
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
SYS-CON Events announced today that DivvyCloud will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. DivvyCloud software enables organizations to achieve their cloud computing goals by simplifying and automating security, compliance and cost optimization of public and private cloud infrastructure. Using DivvyCloud, customers can leverage programmatic Bots to identify and remediate common cloud problems in rea...
SYS-CON Events announced today that Tintri, Inc, a leading provider of enterprise cloud infrastructure, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Tintri offers an enterprise cloud platform built with public cloud-like web services and RESTful APIs. Organizations use Tintri all-flash storage with scale-out and automation as a foundation for their own clouds – to build agile development environments...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs ofte...